ACVR2B antibody (C-Term)

Catalog No. ABIN635186

The Rabbit Polyclonal anti-ACVR2B antibody has been validated for WB. It is suitable to detect ACVR2B in samples from Human and Dog.

Quick Overview for ACVR2B antibody (C-Term) (ABIN635186)

Target: ACVR2B (Activin A Receptor, Type IIB (ACVR2B))

Reactivity: Human, Dog

Host: Rabbit

Clonality: Polyclonal

Conjugate: This ACVR2B antibody is un-conjugated

Application: Western Blotting (WB)

Product Details anti-ACVR2B Antibody

Binding Specificity: C-Term

Specificity: ACVR2 B antibody was raised against the C terminal of ACVR2

Purification: Affinity purified

Immunogen: ACVR2 B antibody was raised using the C terminal of ACVR2 corresponding to a region with amino acids HDAEARLSAGCVEERVSLIRRSVNGTTSDCLVSLVTSVTNVDLPPKESSI

Application Details

Application Notes: WB: 0.25 µg/mL
Optimal conditions should be determined by the investigator.

Comment:

ACVR2B Blocking Peptide, (ABIN939092), is also available for use as a blocking control in assays to test for specificity of this ACVR2B antibody

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Lyophilized powder. Add distilled water for a 1 mg/mL concentration of ACVR0 antibody in PBS

Concentration: Lot specific

Buffer: PBS

Handling Advice: Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use.

Storage: 4 °C/-20 °C

Storage Comment: Store at 2-8 °C for short periods. For longer periods of storage, store at -20 °C.

Target Details for ACVR2B

Target: ACVR2B (Activin A Receptor, Type IIB (ACVR2B))

Alternative Name: ACVR2B

Background: Activin receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling, and type II receptors are required for binding ligands and for expression of type I receptors.

Molecular Weight: 33 kDa (MW of target protein)

Pathways: Hormone Transport, Cancer Immune Checkpoints